130 related articles for article (PubMed ID: 2550842)
1. Haloperidol pretreatment unmasks the kappa opioid effects of U-50, 488H on cortical EEG and EEG power spectra in rats.
Young GA; Marquis KL; Paquette NC; Gussio RP; Khazan N
Neuropharmacology; 1989 Aug; 28(8):881-4. PubMed ID: 2550842
[TBL] [Abstract][Full Text] [Related]
2. Interactions between U-50,488H and sigma receptor antagonists: EEG, EEG power spectral and behavioral correlates.
Young GA; Hudson GM; Stamidis H; Steinfels GF
Eur J Pharmacol; 1993 Feb; 231(3):473-6. PubMed ID: 8095467
[TBL] [Abstract][Full Text] [Related]
3. Effects of morphine in rats treated chronically with U-50,488 H, a kappa opioid receptor agonist.
Bhargava HN; Ramarao P; Gulati A
Eur J Pharmacol; 1989 Mar; 162(2):257-64. PubMed ID: 2542058
[TBL] [Abstract][Full Text] [Related]
4. The selective kappa-opioid agonist, U-50,488H, produces antinociception in the rat via a supraspinal action.
Czlonkowski A; Millan MJ; Herz A
Eur J Pharmacol; 1987 Oct; 142(1):183-4. PubMed ID: 2826175
[No Abstract] [Full Text] [Related]
5. Effects of a selective kappa-opioid agonist, U-50,488H, on morphine dependence in rats.
Fukagawa Y; Katz JL; Suzuki T
Eur J Pharmacol; 1989 Oct; 170(1-2):47-51. PubMed ID: 2558895
[TBL] [Abstract][Full Text] [Related]
6. Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord.
Bhargava HN; Gulati A; Ramarao P
J Pharmacol Exp Ther; 1989 Oct; 251(1):21-6. PubMed ID: 2552075
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.
Pugsley MK; Penz WP; Walker MJ; Wong TM
Br J Pharmacol; 1992 Mar; 105(3):521-6. PubMed ID: 1320979
[TBL] [Abstract][Full Text] [Related]
8. Dissociation of naloxone-sensitive and naloxone-insensitive effects of U-50,488H.
Young GA
Pharmacol Biochem Behav; 1989 May; 33(1):215-7. PubMed ID: 2780779
[TBL] [Abstract][Full Text] [Related]
9. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
Wilson JL; Nayanar V; Walker JS
Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
[TBL] [Abstract][Full Text] [Related]
10. A selective kappa-opioid agonist, U-50,488H, blocks the development of tolerance to morphine analgesia in rats.
Yamamoto T; Ohno M; Ueki S
Eur J Pharmacol; 1988 Oct; 156(1):173-6. PubMed ID: 2850208
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of a selective kappa receptor agonist, U-50, 488H, on methamphetamine-elicited ipsilateral circling behavior in rats with unilateral nigral lesions.
Ohno M; Yamamoto T; Ueki S
Psychopharmacology (Berl); 1989; 97(2):219-21. PubMed ID: 2543013
[TBL] [Abstract][Full Text] [Related]
12. Behavioural effect of pretreatment with opioid antagonists and sigma binding site ligands on the abnormal motor response produced by the kappa opioid agonist U50,488H in guinea pigs.
Brent PJ
Neuropharmacology; 1993 Aug; 32(8):751-60. PubMed ID: 8413839
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of central receptors for thyrotropin-releasing hormone in kappa opiate agonist-induced abstinence in the rat.
Bhargava HN; Gulati A; Rahmani NH
Neuropharmacology; 1992 Feb; 31(2):137-41. PubMed ID: 1313157
[TBL] [Abstract][Full Text] [Related]
14. Effects of acute and chronic administration of dizocilpine on the pharmacological responses to U-50,488H and brain and spinal cord kappa-opioid receptors in the rat.
Bhargava HN; Matwyshyn GA; Gudehithlu KP
Pharmacology; 1995 Nov; 51(5):323-30. PubMed ID: 8584584
[TBL] [Abstract][Full Text] [Related]
15. Serotonergic involvement in the antinociceptive action of and the development of tolerance to the kappa-opioid receptor agonist, U-50, 488H.
Ho BY; Takemori AE
J Pharmacol Exp Ther; 1989 Aug; 250(2):508-14. PubMed ID: 2547935
[TBL] [Abstract][Full Text] [Related]
16. Differential neuropharmacological effects of mu, kappa and sigma opioid agonists on cortical EEG power spectra in the rat. Stereospecificity and naloxone antagonism.
Young GA; Khazan N
Neuropharmacology; 1984 Oct; 23(10):1161-5. PubMed ID: 6097833
[TBL] [Abstract][Full Text] [Related]
17. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
Sheldon RJ; Nunan L; Porreca F
J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of brain and spinal cord K-opiate receptors in spontaneously hypertensive, Wistar-Kyoto normotensive, and Sprague-Dawley rats by chronic treatment with U-50, 488H.
Bhargava HN; Gulati A; Ramarao P
Biochem Pharmacol; 1991 Jun; 42(1):25-9. PubMed ID: 1648922
[TBL] [Abstract][Full Text] [Related]
19. Effect of the kappa-receptor agonist, U-50,488H, on cerebral ischemia-induced impairment of working memory assessed in rats by a three-panel runway task.
Ohno M; Yamamoto T; Ueki S
Eur J Pharmacol; 1991 Feb; 193(3):357-61. PubMed ID: 1647321
[TBL] [Abstract][Full Text] [Related]
20. Multi-dimensional analyses of behavior in mice treated with U-50,488H, a purported kappa (non-mu) opioid agonist.
Ukai M; Kameyama T
Brain Res; 1985 Jul; 337(2):352-6. PubMed ID: 2992682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
